A Phase 2 interventional study of Omaveloxolone Lotion 0.5% and Omaveloxolone Lotion 3% in Breast Cancer, sponsored by Biogen. Completed at 27 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Biogen · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting toxicity requiring changes to the prescribed course of radiation therapy. The most common strategy employed in an attempt to prevent or minimize radiation dermatitis involves moisturization of the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants, such as scratching and rough clothing. However, this strategy has been shown to lack clinically significant efficacy. Consequently, there is a clinical need for new treatments that are effective in protecting against radiotherapy-induced oxidative stress and the subsequent development of radiation dermatitis.
Based on data from previous studies in animals and humans, Reata believes that omaveloxolone (RTA 408) Lotion may effectively prevent and mitigate radiation dermatitis in oncology patients undergoing radiation therapy.
This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's enrollment of 187 is above the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients planning to undergo 3D conformal radiation therapy to the whole breast (as part of breast-conservation therapy / lumpectomy) or chest wall (as part of post-mastectomy irradiation), with or without treatment of regional lymph nodes (i.e., axillary, supraclavicular, or internal mammary), using one of the following treatment schedules:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Omaveloxolone Lotion at a fixed dose of 0.5% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)
Drug: Omaveloxolone Lotion 0.5% · Radiation: 3D conformal radiation therapy
Omaveloxolone Lotion at a fixed dose of 3% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 19 weeks)
Drug: Omaveloxolone Lotion 3% · Radiation: 3D conformal radiation therapy
Vehicle Lotion administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)
Drug: Vehicle Lotion · Radiation: 3D conformal radiation therapy
Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Also known as: RTA 408 Lotion 0.5%
Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Also known as: RTA 408 Lotion 3%
Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle
CTCAE Radiation dermatitis scoring: Grade 0 = No radiation dermatitis; Grade 1 = Faint erythema or dry desquamation; Grade 2 = Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin folds and creases, moderate edema; Grade 3 = Moist desquamation in areas other than skin folds and creases, bleeding induced by minor trauma or abrasion; Grade 4 = Life-threatening consequences, skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from involved site, skin graft indicated; Grade 5 = Death
Time frame: Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported
| Milestone | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion |
|---|---|---|---|
| Started | 64 | 62 | 61 |
| Completed | 59 | 59 | 55 |
| Not completed | 5 | 3 | 6 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 3 |
| Withdrew: Administrative reasons | 1 | 0 | 1 |
| Withdrew: Missing | 0 | 1 | 0 |
| Withdrew: Treatment changed from radiation treatment to chemo | 0 | 0 | 1 |
| Withdrew: Patient didn't complete end of study visit | 0 | 0 | 1 |
CTCAE Radiation dermatitis scoring: Grade 0 = No radiation dermatitis; Grade 1 = Faint erythema or dry desquamation; Grade 2 = Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin folds and creases, moderate edema; Grade 3 = Moist desquamation in areas other than skin folds and creases, bleeding induced by minor trauma or abrasion; Grade 4 = Life-threatening consequences, skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from involved site, skin graft indicated; Grade 5 = Death
| Grade | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion |
|---|---|---|---|
| Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle | 1.1 (1.0 to 1.2) | 1.2 (1.1 to 1.3) | 1.2 (1.1 to 1.3) |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Omaveloxolone (RTA 408) Lotion 0.5% | 0/64 (0%) | 4/64 (6.3%) | 49/64 (76.6%) |
| Omaveloxolone (RTA 408) Lotion 3% | 1/62 (1.6%) | 3/62 (4.8%) | 54/62 (87.1%) |
| Vehicle Lotion | 0/61 (0%) | 0/61 (0%) | 50/61 (82%) |
| Event | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/64 | 1/62 | 0/61 |
| Carbon monoxide poisoningInjury, poisoning and procedural complications | 0/64 | 1/62 | 0/61 |
| InjuryInjury, poisoning and procedural complications | 0/64 | 1/62 | 0/61 |
| Cardiac failure congestiveCardiac disorders | 1/64 | 0/62 | 0/61 |
| CardiomyopathyCardiac disorders | 1/64 | 0/62 | 0/61 |
| Incision site cellulitisInfections and infestations | 1/64 | 0/62 | 0/61 |
| Alanine aminotransferase increasedInvestigations | 1/64 | 0/62 | 0/61 |
| DehydrationMetabolism and nutrition disorders | 1/64 | 0/62 | 0/61 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/64 | 0/62 | 0/61 |
| AnxietyPsychiatric disorders | 1/64 | 0/62 | 0/61 |
| Event | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion |
|---|---|---|---|
| FatigueGeneral disorders | 27/64 | 27/62 | 26/61 |
| Breast painReproductive system and breast disorders | 20/64 | 19/62 | 18/61 |
| PruritusSkin and subcutaneous tissue disorders | 20/64 | 17/62 | 12/61 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 19/64 | 15/62 | 18/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/64 | 3/62 | 6/61 |
| NauseaGastrointestinal disorders | 5/64 | 3/62 | 5/61 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/64 | 3/62 | 2/61 |
| HeadacheNervous system disorders | 3/64 | 2/62 | 4/61 |
| Hot flushVascular disorders | 3/64 | 4/62 | 4/61 |
| Upper respiratory tract infectionInfections and infestations | 4/64 | 1/62 | 2/61 |
Intent-to-treat population (all randomized patients whether or not they received study drug)
| Age, Continuous(years) | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion | Total |
|---|---|---|---|---|
| Mean | 57.7 ± 8.8 | 56 ± 10.2 | 56.6 ± 10.3 | 56.8 ± 9.8 |
| Sex: Female, Male(Participants) | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion | Total |
|---|---|---|---|---|
| Female | 64 | 62 | 61 | 187 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 5 | 11 |
| Not Hispanic or Latino | 61 | 58 | 56 | 175 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 13 | 6 | 5 | 24 |
| White | 50 | 54 | 51 | 155 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 2 | 5 |
| Region of Enrollment(participants) | Omaveloxolone (RTA 408) Lotion 0.5% | Omaveloxolone (RTA 408) Lotion 3% | Vehicle Lotion | Total |
|---|---|---|---|---|
| United States | 64 | 62 | 61 | 187 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Jun 2014 to primary completion in Apr 2015, 10 months.
Results were first posted in May 2023, 8 years after primary completion. A results delay was requested in Jun 2015.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 10 months is below that.
Counting every sponsor, half of 1,303 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.